In 2023 and 2024, the American Academy of Dermatology (AAD) released updated guidelines for managing atopic dermatitis (AD) in adults, focusing on both topical and systemic therapies. Since then, new FDA-approved treatments have become available, prompting the AAD to revisit and expand its recommendations.
Purpose of the Update
The goal was to provide updated, evidence-based guidance on incorporating newly approved therapies into the management of adult AD.
How the Guidelines Were Developed
A multidisciplinary panel of experts conducted a systematic review of the current evidence and applied the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) framework to assess the strength and certainty of their recommendations.
Key Findings
The updated guidelines include four new treatment recommendations, specifically endorsing the use of:
Limitations
While these recommendations are based on the best available evidence, most clinical trials of the newer treatments have been relatively short-term. As a result, long-term safety and efficacy comparisons remain limited.
Bottom Line
These updates reflect important advances in the treatment landscape for atopic dermatitis and offer dermatology practitioners more tools to tailor care for adults living with this chronic skin condition.
For a link to the original article in the JAAD, click here
Elevate-Derm Alliance Editorial Committee